news

Pfizer COVID-19 vaccine set to generate sales of $30 billion

9
SHARES

Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.

Pfizer COVID-19 vaccine

According to new reports, the COVID-19 vaccine produced by Pfizer and BioNTech, BNT-162b2, is currently projected to generate at least $30 billion in sales from 2020 to 2026. GlobalData, which released the research, said that the vaccine would peak with sales in 2021 worth $13.9 billion. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The report highlights that the Pfizer-BioNTech vaccine, a two-shot mRNA COVID-19 inoculation, is the leading prophylactic to combat COVID-19 based on forecast sales, as it is expected to be the first globally available vaccine to prevent the spread of SARS-CoV-2.   

Keshalini Sabaratnam, Pharma Analyst at GlobalData, commented: “Despite being the first available vaccine, BNT-162b2’s sales are forecasted to decline by a staggering 76 percent in 2022 to $3.4 billion due to competition expected from future COVID-19 vaccine approvals. Nonetheless, COVID-19 vaccines will continue to be in demand beyond 2022 if COVID-19 turns out to be a seasonal or a long-term concern.”

The researchers say that the main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics, whereas Moderna’s vaccine candidate mRNA-1273, which can be stored and shipped at -20°C, could be a more attractive alternative.

Vaccine sales

“Pfizer-BioNTech’s BNT-162b2 vaccine breakthrough marks a significant turning point in the global battle against COVID-19. It raises hopes that life could return to normal by next winter; however, post-marketing surveillance will be critical to detect any rare serious adverse events, as there has not yet been an mRNA vaccine that has gone through the full regulatory pathway for approval,” said Sabaratnam. 

Related organisations

, , ,

Related drugs

,

Related people

Related diseases & conditions

Share via
Share via